Investors might want to bet on Werewolf Therapeutics, Inc. (HOWL), as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). This rating change essentially reflects an upward trend in earnings ...

Werewolf Therapeutics, Inc. (HOWL) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, ...

Werewolf Therapeutics, Inc. (HOWL) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #1 (Strong Buy). This upgrade is essentially a reflection of an upward trend in ...

Investors might want to bet on Werewolf Therapeutics, Inc. (HOWL), as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, ...

Werewolf Therapeutics (HOWL) has made great progress thus far in advancing its IL-2 drug known as WTX-124 for the treatment of patients with advanced or metastatic solid tumors. It has an ongoing ...

HOWL is in the clinic with both WTX-124 and WTX-330 and is set to report initial data from the phase 1 trial of WTX-124 in Q4'23. HOWL's partner JAZZ should file an Investigational New Drug ...

Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to ...

Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to ...